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sought to examine the risk of subsequent ST associated with any DAPT interruption
(aspirin or thienopyridine) with XIENCE V everolimus-eluting coronary stent systems
(EES) (Abbott Vascular, Santa Clara, CA) in 13,259 patients from 7 studies (3 pre-
approval [SPIRIT II, III, IV] and 4 post-marketing [SPIRIT V and SPIRIT Women,
XIENCE V USA, XIENCE V India].
Methods: Definite/probable ST was adjudicated per ARC definition by an independent
clinical events committee. Analyses were conducted to assess overall ST rates and the
relationship between first DAPT interruption and subsequent ST.
Results: 2-year follow-up was complete in 12,552 pts, of whom ST occurred in 93 pts
(0.74%). By Kaplan-Meier analysis the 2-year ST rate was 0.71%. ST rates landmarked
sequentially from 30, 90, 180 and 365 d were 0.34%, 0.06%, 0.07%, 0.14%,
respectively. DAPT interruption data at different time intervals appears in the Table.
Conclusion: In this analysis of 13,259 patients receiving EES in a broad cross-section
of geographies, patients and lesions, 2-year cumulative ST rates were 0.74%. DAPT
interruption before 30 days was strongly associated with increased ST. Conversely, ST
rates were not increased with DAPT discontinuation after 30 days in patients who
received EES.
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Background: There are limited data about differences in outcome after stent
thrombosis (ST) according to the timing of the event.
Methods: A total of 3,602 pts with ST-segment elevation myocardial infarction
(STEMI) treated with primary percutaneous coronary intervention (PCI) were included
in HORIZONS-AMI. Stents were implanted in 3,202 pts. During 3-year follow-up
ARC-defined definite/probable ST occurred in 156 pts (4.9%). We compared 1-year
clinical outcomes after ST according to the timing of the event; acute (<24 hours),
subacute (24 hours-30 days), late (30 days-1 year), and very late (1 year-3 years).
Results: Acute ST occurred in 28 pts (18%), subacute ST in 48 pts (31%), late ST in
30 pts (19%), and very late ST in 50 pts (32%). One year mortality is shown in Figure
1. Subacute ST had the highest 1-year mortality (39.7%) while mortality for other ST
types was <10%. Most deaths occurred within the first weeks after the ST event. Rates
of reinfarction were higher in patients with late (77.1%) and very late ST (86.0%)
compared with acute (57.1%) and subacute ST (59.3%, p for trend <0.01). The
composite endpoint of death/reinfarction occurred with similar frequency in all ST
types (acute 64.3%, subacute, 83.3%, late 80.0%, very late 86.0%, p for trend
0.13).Major bleeding was more frequent in patients with acute (26.8%) and subacute
ST (13.6%) compared with late (3.7%) and very late ST (6.3%, p for trend 0.03).
Conclusion: This large cohort of patients with ST after primary PCI for STEMI
showed that mortality was highest after subacute ST. Reinfarction was less frequent,
and major bleeding was more frequent in patients with acute and subacute ST compared
with late and very late ST.
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Background: The aim of this study is to compare the safety and efficacy of Sirolimus
(SES), Paclitaxel (PES), EPC capture (ECS), Zotarolimus (ZES-R/ Endeavor
Resolute), BiolimusA9 (BES) and Everolimus-eluting stent (EES) on the outcome of
percutaneous coronary intervention in patients with diabetes mellitus (DM).
Methods: A prospective analysis of 2972 patients with DM (808 SES, 720 PES, 299
ECS, 404 ZES-R, 320 BES, 421 EES) in six high volume Asian centers after successful
stenting was performed. The study endpoints were 30 days major adverse cardiac
events (MACE) and 12, 24 and 36 months target lesion revascularization (TLR) and
MACE.
Results: See table for clinical results.
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Conclusion: The use of drug-eluting stents in patient with DM was safe with low acute
complication. Patients treated with BES and EES showed lesser rate of restenosis
compared with ECS.
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Background: The RESOLUTE Clinical Program comprises 5 trials worldwide
evaluating the Resolute zotarolimus-eluting stent (R-ZES), which were prospectively
designed with similar methods including: data collection forms, adverse event
definitions and adjudication procedures, statistical programming algorithms and data
sets to allow pooling. The R-ZES is a contemporary drug-eluting stent composed of a
thin-strut cobalt alloy BMS and a proprietary polymer with hydrophilic properties for
biocompatibility and hydrophobic properties for uniform prolonged drug release (85%
delivered by 60 days; remaining up to 180 days). Extended elution may better balance
arterial healing, and any associated sustained proliferative stimuli, in high-risk patients
such as those with diabetes mellitus (DM). We will present pooled clinical outcomes
at 1-year for patients with DM treated with the R-ZES.
Methods: To date, 5130 patients have been enrolled in 247 centers in 5 R-ZES Trials
(Resolute First-In-Man [139], Resolute All Comers [1140], Resolute International
[2349], Resolute United States [1402], Resolute Japan [100]). We compared baseline
characteristics and clinical outcomes at 1 year for 1535 patients with DM vs those
without DM, as well as by insulin requirements.
Results: Of 1535 patients with DM, 455 (29.6%) were insulin treated. At baseline DM
patients were older, more were female, with hyperlipidemia, hypertension, previous
coronary artery bypass grafting, and moderate/severe calcification. At 1 year, the rates
of target lesion failure (cardiac death, target-vessel MI, clinically-driven TLR) were
7.8% for DM vs. 6.1% for non-DM (p=0.03); patient-oriented composite (all death,
all MI, all revascularization) (15.6% vs. 12.1%, p < 0.001); cardiac death and target-
vessel-related MI (4.7% vs. 3.6%, p = 0.08); clinically-driven TLR (4.0%vs. 2.9%,
p=0.06); and ARC definite and probable ST (1.1% vs. 0.7%, p=0.17). We will also
report outcomes by insulin requirements.
Conclusion: In this large diverse patient cohort with DM, the R-ZES had low event
rates despite the high-risk nature of this population.
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Background: Diabetes is associated with an increased risk of major adverse cardiac
events (MACE) following percutaneous coronary intervention. In this substudy of the
SORT OUT IV trial, we compared the clinical outcome among patient with and without
diabetes mellitus treated with everolimus-eluting (EES) or sirolimus-eluting (SES).
Methods: Of 2,774 patients, 390 (14.1%) patients had diabetes and were treated with
EES (n=1,390, diabetes: n = 194) or SES (n = 1,384, diabetics: n=196). Randomization
was stratified by presence/absence of diabetes. The primary endpoint was MACE,
defined as a composite of cardiac death, myocardial infarction (MI), definite stent
thrombosis or target vessel revascularization within 18 months.
Results: At 18-month, MACE were higher among diabetic patients (diabetic patients:
13.1% vs. non-diabetic patients: 6.4%; Hazard ratio (HR) 95% confidence interval
2.08 (1.51 - 2.86). At 18-month MACE was 10.3% in the EES- and 15.8% in the SES-
treated diabetic patients (HR 0.63 95% CI 0.36-1.11) and 6.6% in the EES- and 6.3 in
the SES-treated patients without diabetes (HR 1.06 95% CI 0.77-1.46). In diabetic
patients cardiac death 3.1% in EES- and 4.6% in SES-treated patients (HR 0.67 95%
CI 0.24-1.89), MI 0.5% in EES- and 3.6% in SES-treated patients (HR 0.14 95% CI
0.02-1.16) and clinically driven target lesion revascularization 3.1% in EES- and 7.7%
in SES-treated patients (HR 0.40 95% CI 0.15-1.02) did not differ between EES and
SES treated patients. Definite stent thrombosis was not seen in diabetic patients treated
with EES compared to 4 patients treated with SES.
Conclusion: EES showed a non-significant reduced risk of MACE compared to SES
in patients with diabetes mellitus.
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Background: Critical Limb Ischemia (CLI) with or without lower extremity
amputation (LEA) is reported as an independent predictor of cardiac mortality in
diabetic patients and these deaths are related to the high prevalence of CAD in these
subjects. The aim of our study was to investigate the impact on long-term cardiac
mortality of the association of CAD with CLI in diabetic patients and the potential
effect of coronary and limb revascularization
Methods: The study was designed as a prospective single centre registry which
enrolled and followed for 4 years 764 consecutive diabetic patients undergoing
percutaneous coronary intervention (PCI), between July 2002 and May 2007. The
development of CLI was diagnosed by a dedicated diabetic foot-clinic specialist. All
patients with CLI underwent peripheral revascularization of the culprit limb. Cardiac
mortality was the primary endpoint of the study.
Results: Among the 764 PCI patients, 111 (14%) developed CLI during follow-up
(PCI+CLI group) and were treated with peripheral intervention in 145 limbs with
procedural success in 140 (96%). PCI+CLI patients had lower left ventricle ejection
fraction (LVEF) (51±11% vs 53±10%, p=0.008) higher renal failure (25% vs 12%,
p=0.005), dialysis (7% vs 0.3%, p<0.0001) and diabetes duration (13.8 vs 11.7 years,
p=0.02) compared to PCI-only patients. Coronary intervention procedural
characteristics did not differ among PCI-only and PCI-CLI patients. At 4-year follow
up, cardiac mortality occurred in 10(9%) PCI-CLI vs 39(6%) PCI-only patients
(p=0.2). Major amputation occurred in 6(5%) patients. Cox regression analysis showed
age (OR 1.06, 95%CI 1.02-1.09), dialysis (OR 8.02, 95%CI 4.02-18.3) and LVEF<30%
(OR 9.40, 95%CI 4.20-20.61) to be the independent predictors of cardiac mortality
which was not influenced by the development of CLI (OR 0.93, 95%CI 0.42-2.06).
Conclusion: In diabetic patients treated with percutaneous coronary revascularization,
the development of CLI, treated with peripheral intervention, seems not to impact
cardiac mortality long terms.
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Background: In acute myocardial infarction (AMI) patients treated with percutaneous
coronary intervention (PCI), presence of diabetes mellitus (DM) imparts worse
cardiovascular outcomes. In this study, we evaluated the influence of glycemic control
on clinical outcomes in DM patients with AMI after successful PCI.
Methods: We examined 231 consecutive DM patients with AMI who underwent
successful primary PCI and had evaluation of glycosylated hemoglobin (HbA1c) from
30 days before to 90 days after AMI. Patients were categorized in two groups,
controlled DM with HbA1c ≤ 7.0 (N=83, 36%) and uncontrolled DM with HbA1c >
7.0 (N = 148, 64%). We assessed 12-month cardiovascular outcomes in study groups.
Results: Uncontrolled diabetics were younger, tended to be less hypertensive, and had
higher baseline glomerular filtration rate and final vessel diameter compared to
controlled diabetics. Uncontrolled DM patients had similar MACE [composite of all-
cause death, myocardial infarction (MI), target vessel revascularization (TVR), and
stent thrombosis (ST); (20 vs. 30%, log rank p=0.54, figure], death (8.8 vs. 12%,
p=0.40), MI (8.8 vs. 9.6%, p=0.76), TVR (9.5 vs. 8.4%, p=0.95) and ST (3.4 vs. 4.8%,
p=0.54) as the controlled diabetics. In Cox regression analysis, after adjustment for
baseline differences, glycemic control had no independent influence on study
outcomes.
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